Please ensure Javascript is enabled for purposes of website accessibility
Alex Carchidi

Alex Carchidi

TMFacarchidi

Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. His interests include exploring his hometown of Boston, traveling in Latin America, and value investing.

Recent articles

cannabis seller weighs cannabis

Where Will Tilray Brands Be in 3 Years?

Its future depends on how effectively it can navigate cannabis legalization in potential major markets.


scientist studies test tube

3 Unstoppable Stocks That Don't Care About the Bear Market

When the market is falling, this trio keeps rising.


exasperated investor consults tablet

Prediction: This Bear Market Will Test Your Resolve In (At Least) 3 Ways

Your portfolio is counting on you to pass the tests.


cannabis farmer holds ipad and smiles

3 Things About Sundial Growers That Smart Investors Know

Not a whole lot is going right, but it isn't as bad as it might look.


doctor does telehealth visit while in her kitchen

Is There any Hope for Teladoc Stock in 2023?

Its recent performance leaves a lot to be desired.

investor considers screen while writing on pad

Buying Shares of These 2 Monster Stocks on the Dip Could Be a Genius Move

They're the undisputed leaders of their markets.


investors analyzes data on large screen

Should You Really Be Buying Beaten-Down Growth Stocks Right Now?

Now's a great time to invest in companies with the potential to grow significantly in the long term.


two investors look at figures

3 Reasons Why AbbVie Stock Could Be Approaching a Make or Break Moment

It won't be able to rely on Humira for growth for much longer.


cannabis farmer inspects plant in field

2 Red Flags and 2 Green Flags for Tilray Stock

It's having trouble at home, but it could soon get a huge gift from European regulators.


investor looks at book with consternation

3 Things Most Investors Don't Know About Warren Buffett's Investing Style

There's a lot more to value investing than picking companies with evergreen business models.

doctor points to pill bottle while explaining to patient

Could This Unknown Stock Beat Moderna in 2023?

Vaxart is still in the coronavirus vaccine race, even though its competitors remain very far ahead.


investor consider papers and laptop while sitting in cafe

2 Growth Stocks That Are Unapologetically Crushing the Bear Market

There's more than one factor driving recent outperformance of these shares.


cannabis worker examines cannabis plant with scope

3 Early Signs This Crushed Growth Stock Might Be in a Turnaround

Aurora Cannabis still has a long way to go, but a few key things are going right.


two investors look at figures

3 Things the Smartest Investors Do When the Market Is Crazy

They stay focused on the long term and act accordingly.


investor talks with two coworkers

Do These 3 New Moneymakers for AstraZeneca Make It a Buy?

Cranking out new medicines is business as usual, but these three could be big earners.

GettyImages-482140867

Is Abbott Laboratories a Buy?

This stock rewards investors who have patience.


stressed investor sitting in dark at computer

2 Potential Headwinds and 2 Potential Tailwinds for InMode Stock in August

InMode's margin is under pressure from multiple points, but it probably won't matter.


two doctors talk at conference room

3 Key Questions That Pfizer Will Answer This Week

Paxlovid's performance will be the most important issue to clarify.


doctor consults with patient

2 Reasons Why DexCom Stock Could Be a Smart Buy This Week

Its global ambitions are poised to drive further returns.


investor sitting with laptop and dog

3 No-Brainer Warren Buffett Stocks That Will Undeniably Profit from the Bear Market

These unstoppable companies can succeed in pretty much any economic condition.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.